EU funded Projects related to this Project include:
Mechanisms of prevention of type 2 diabetes by lifestyle intervention in subjects with pre-diabetes or at risk for progression.
Project Number : 279228
Website : http://dexlife.eu
EuroStemCell, launched in March 2010, unites more than 90 European stem cell and regenerative medicine research labs in a coordinated effort to engage with the public about our science. We’re a partnership of scientists, clinicians, ethicists, social scientists and science communicators. We believe in making research on stem cells and regenerative medicine accessible to all.
Project Number : 241878
Website : http://www.eurostemcell.org/
STELLAR is a research consortium consisting of European and Australian researchers interested in developing an alternative to renal replacement therapy. The STELLAR consortium will make use of newly discovered kidney mesenchymal stromal cells (kMSC). kMSC have the potential to regenerate and repair damaged tissue. By injecting kMSC into affected kidneys the research consortium expects to stop kidney fibrosis and induce tissue repair, ultimately leading to the restoration of normal kidney function.
Project Number : 305436
Website : http://www.stellarproject.eu/
The overall aim of CommHERE is to improve communication on the outcome of EU funded health research projects to the media, the general public and other target groups including the EC in all of Europe.
Project nr = 282539
DECIDE is a Marie Curie initial training network (ITN) programme funded by the European Union under the FP7 programme. DECIDE aims to advance understanding of normal blood cell development and why primitive cells fail to differentiate in acute myeloid leukaemia (AML). We will use the information gained to develop ways of alleviating the differentiation block in AML and so deliver new agents, including novel vitamin D and retinoid analogues, for use in differentiation therapy. This type of therapy aims to respond to the urgent need to devise milder treatments, especially for older and frailer AML patients.
Project number 315902
VISICORT is a multi-disciplinary project with expertise in basic immunology, bio-sampling, systems biology/immune profiling, bioinformatics, clinical tissue transplantation and cell therapy. It will complete the first systematic immune profiling of biological samples from animal and human CT recipients with diverse outcomes.
Project number 602470
The EUROCONDOR project is studying an innovative therapeutic strategy using eye drops to combat diabetic retinopathy, the leading cause of blindness among working-age individuals in developed countries. Funded by the European Commission’s FP7, the 4 year project involves 17 partners across Europe. EUROCONDOR combines expertise in endocrinology, ophthalmology and basic research together with clinical trial knowledge and know-how in diabetes advocacy.
Project number 278040
MERLIN explores exciting new opportunities in stromal cell therapy R&D, while making important contributions to the treatment of currently intractable inflammatory and immune mediated liver diseases.
Project number: 602363
NEPHSTROM will deliver and validate a transformative mesenchymal stem cell (MSC) treatment, which has already demonstrated the potential to target the five major aspects of DKD – hypertension, inflammation, fibrosis, oxidative stress, and proteinuria – with a single treatment.
Project nr = 634086
To make successful therapies available to all patients it is necessary to grow these cells in a fast, safe and controlled manner, while minimizing the costs for production. Together, the partners in REACH work towards a novel bioreactor system that will make the production of cell therapies easier and more cost-efficient.
RETHRIM is an EU sponsored consortium that has initiated a phase III clinical trial to investigate the usefulness of mesenchymal stromal cells for the treatment of Graft-Versus-Host-Disease (GVHD).
Project nr = 643580